Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 15/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478356 | 0.85 | MAPK14 (0.61) | MAPK14MCHR1KCNH2NSD2ABL1 | |
| SCHEMBL23534909 | 0.85 | MAPK14 (0.54) | MAPK14MCHR1KCNH2 | |
| SCHEMBL18500627 | 0.83 | MAPK14 (0.52) | MAPK14MCHR1KCNH2 | |
| SCHEMBL4468416 | 0.82 | MAPK14 (0.54) | MAPK14MCHR1KCNH2 | |
| SCHEMBL16753140 | 0.81 | MAPK14 (0.50) | MAPK14MCHR1KCNH2 | |
| SCHEMBL19470113 | 0.81 | MAPK14 (0.56) | MAPK14MCHR1KCNH2PPARGL3MBTL1 | |
| SCHEMBL19470112 | 0.81 | MAPK14 (0.56) | MAPK14MCHR1KCNH2PPARGL3MBTL1 | |
| SCHEMBL5297735 | 0.80 | MAPK14 (0.66) | MAPK14MCHR1KCNH2NSD2ABL1 | |
| SCHEMBL935579 | 0.79 | MAPK14 (0.48) | MAPK14MCHR1KCNH2 | |
| SCHEMBL16753139 | 0.79 | MAPK14 (0.50) | MAPK14MCHR1KCNH2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | MAPK14 3776/4885MCHR1 994/4885KCNH2 69/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | MAPK14 3776/4885MCHR1 994/4885KCNH2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.